pCMV4-BlaM-Vpr Citations (13)
Originally described in: A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes.Cavrois M, De Noronha C, Greene WC Nat Biotechnol. 2002 Nov . 20(11):1151-4. PubMed Journal
Articles Citing pCMV4-BlaM-Vpr
| Articles |
|---|
| Systematic identification of synergistic drug pairs targeting HIV. Tan X, Hu L, Luquette LJ 3rd, Gao G, Liu Y, Qu H, Xi R, Lu ZJ, Park PJ, Elledge SJ. Nat Biotechnol. 2012 Nov;30(11):1125-30. doi: 10.1038/nbt.2391. Epub 2012 Oct 14. PubMed |
| Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Fenard D, Ingrao D, Seye A, Buisset J, Genries S, Martin S, Kichler A, Galy A. Mol Ther Nucleic Acids. 2013 May 7;2:e90. doi: 10.1038/mtna.2013.17. PubMed |
| Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Ingrao D, Majdoul S, Seye AK, Galy A, Fenard D. Hum Gene Ther Methods. 2014 Feb;25(1):48-56. doi: 10.1089/hgtb.2013.090. Epub 2013 Nov 20. PubMed |
| HIV-1 induces the formation of stable microtubules to enhance early infection. Sabo Y, Walsh D, Barry DS, Tinaztepe S, de Los Santos K, Goff SP, Gundersen GG, Naghavi MH. Cell Host Microbe. 2013 Nov 13;14(5):535-46. doi: 10.1016/j.chom.2013.10.012. PubMed |
| Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV. Wilkins J, Zheng YM, Yu J, Liang C, Liu SL. PLoS One. 2016 Jun 3;11(6):e0156739. doi: 10.1371/journal.pone.0156739. eCollection 2016. PubMed |
| HIV-1 Fusion Assay. Cavrois M, Neidleman J, Greene WC. Bio Protoc. 2014 Aug 20;4(16). pii: e1212. PubMed |
| Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers. Das DK, Govindan R, Nikic-Spiegel I, Krammer F, Lemke EA, Munro JB. Cell. 2018 Aug 9;174(4):926-937.e12. doi: 10.1016/j.cell.2018.05.050. Epub 2018 Jun 28. PubMed |
| mTOR inhibitors lower an intrinsic barrier to virus infection mediated by IFITM3. Shi G, Ozog S, Torbett BE, Compton AA. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10069-E10078. doi: 10.1073/pnas.1811892115. Epub 2018 Oct 9. PubMed |
| Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. Joshi VR, Newman RM, Pack ML, Power KA, Munro JB, Okawa K, Madani N, Sodroski JG, Schmidt AG, Allen TM. PLoS Pathog. 2020 May 11;16(5):e1008577. doi: 10.1371/journal.ppat.1008577. eCollection 2020 May. PubMed |
| Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2. Shi G, Chiramel AI, Majdoul S, Lai KK, Das S, Beare PA, Andresson T, Best SM, Compton AA. bioRxiv. 2021 Apr 16. doi: 10.1101/2021.04.15.440067. PubMed |
IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro.
Prelli Bozzo C, Nchioua R, Volcic M, Koepke L, Kruger J, Schutz D, Heller S, Sturzel CM, Kmiec D, Conzelmann C, Muller J, Zech F, Braun E, Gross R, Wettstein L, Weil T, Weiss J, Diofano F, Rodriguez Alfonso AA, Wiese S, Sauter D, Munch J, Goffinet C, Catanese A, Schon M, Boeckers TM, Stenger S, Sato K, Just S, Kleger A, Sparrer KMJ, Kirchhoff F.
Nat Commun. 2021 Jul 28;12(1):4584.
PubMed
Associated Plasmids |
| T cell migration potentiates HIV infection by enhancing viral fusion and integration. Lopez P, Ajibola O, Pagliuzza A, Zayats R, Koh WH, Herschhorn A, Chomont N, Murooka TT. Cell Rep. 2022 Feb 22;38(8):110406. doi: 10.1016/j.celrep.2022.110406. PubMed |
| Dynamic Ca(2+) sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. Singh P, Mukherji S, Basak S, Hoffmann M, Das DK. Cell Rep. 2022 Apr 19;39(3):110694. doi: 10.1016/j.celrep.2022.110694. Epub 2022 Apr 9. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.